Have a personal or library account? Click to login
Premalignant gastric lesions in patients included in National colorectal cancer screening Cover

Premalignant gastric lesions in patients included in National colorectal cancer screening

Open Access
|Dec 2017

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-386. 10.1002/ijc.2921025220842
  2. Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T. Cancer burden in Slovenia with the time trends analysis. Radiol Oncol 2017; 51: 47-55. 10.1515/raon-2017-000828265232
  3. IARC/WHO. Helicobacter pylori eradication as a strategy for preventing gastric cancer. International Agency for Research on Cancer/World Health Organisation; 2014. [citated 2017 Avg 15]. Available at http://www.iarc.fr/en/publications/pdfs-online/wrk8/ or www.iarc.fr/en/publications/pdfs-online/wrk8/. ISBN 978-92-832-2454-9
  4. Malfertheiner P, Megraud F, O ’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection–the Maastricht V/Florence Consensus Report. Gut 2017; 66: 6-30. 10.1136/gutjnl-2012-30208427707777
  5. Nakajima S. Gastric cancer screening in Japan, now and tomorrow. Nihon Rinsho 2012; 70: 1686-93. 10.1007/s10120020000023198546
  6. Choi IJ. Screening and surveillance of gastric cancer. Korean J Gastroenterol 2007; 49: 15-22. 10.4166/kjg.2009.54.2.67
  7. Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O Connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012; 44: 74-94. 10.1055/s-0031-1291491
  8. Tepeš B. Kavalar R. [Gastric cancer, screening possibilities and proposals for endoscopic and histologic follow-up of premalignant gastric lesions]. [Slovenian]. Zdrav Vestn 2010; 79: 366-74. https://doi.org/10.6016/290
  9. Yuan Y. A survey and evaluation of population-based screening for gastric cancer. Cancer Biol Med 2013; 10: 72-80. 10.7497/j.issn.2095-3941.2013.02.00223882421
  10. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9. 10.1056/NEJMoa00199911556297
  11. Syrjänen K. A Panel of Serum Biomarkers (GastroPanel®) in Non-invasive diagnosis of atrophic gastritis. Systematic review and meta-analysis. Anticancer Res 2016; 36: 5133-44. 10.21873/anticanres.1108327798873
  12. Matsushima M, Miki K, Ichinose M, Kakei N, Yahagi N, Suzuki T, et al. The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer. In: Takahashi K, editor. Aspartic proteinases: advances in experimental medicine and biology. New York: Plenum Press; 1995. p. 139-43.
  13. Screening, early detection and treatment of cancer in China. Dong ZW, editor. Beijing: People’s Medical Publishing House; 2009.
  14. Early detection and treatment of cancer committee. Technical solution on early detection and treatment of cancer in China. Beijing: People’s Medical Publishing House; 2011.
  15. Sipponen P. Biomarkers in clinical practice: a tool to find subjects at high risk for stomach cancer. A personal view. Adv Med Sci 2006; 51: 51-3.17357277
  16. Väänänen H, Vauhkonen M, Helske T, Kääriäinen I, Rasmussen M, Tunturi-Hihnala H, et al. Nonendoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003; 15: 885-91. 10.1097/01.meg.0000059169.46867.01
  17. Agréus L, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di Mario F, Leja M, et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 2012; 47: 136-47. 10.3109/00365521.2011.64550122242613
  18. Dixon M, Genta R, Yardley J, Correa P. Classification and grading of gastritis: the updated Sydney System. Am J Surg Pathol 1996; 10: 1161-81.
  19. Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007; 56: 631-6. 10.1136/gut.2006.10666617142647
  20. Capelle LG, de Vries AC, Haringsma J. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010; 71: 1150-8. 10.1016/j.gie.2009.12.02920381801
  21. Tepeš B, Štabuc B. Slovenian society for gastroenterology and hepatology guidelines on the management of Helicobacter pylori infection. [Slovenian]. Zdrav Vestn 2011; 80: 647-56. https://doi.org/10.6016/216
  22. Syrjänen KJ, Sipponen P, Härkönen M, Peetsalu A and Korpela S. Accuracy of GastroPanel testing in detection of atrophic gastritis. Eur J Gastroenterol Hepatol 2015; 27: 102-4. 10.1097/MEG.0000000000000215
  23. Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008; 38: 259-67. 10.1093/jjco/hyn01718344316
  24. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, et al. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci 2010; 25: 1113-21. 10.3346/jkms.2010.25.8.111320676319
  25. Miki K, Ichinose M, Kawamura N, Matsushima M, Ahmad HB, Kimura M, et al. The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects. Jpn J Cancer Res 1989; 80: 111-4.249824510.1111/j.1349-7006.1989.tb02276.x
  26. Zhang X, Xue L, Xing L, Wang J, Cui J, Mi J, et al. Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14year follow up result in a rural Chinese community. Int J Cancer 2012; 130: 1614-9. 10.1002/ijc.26172
  27. Yuan Y. Population-based gastric cancer screening in Zhuanghe, Liaoning, from 1997 to 2011. Zhonghua Zhong Liu Za Zhi 2012; 34: 538-42.22967474
  28. Tepeš B, Štabuc B. Slovenian Association for Gastroenterology and hepatology recommendations for the management of patients infected with Helicobacter pylori. Zdrav Vestn 2017 (in press).
  29. Sipponen P, Graham DY. Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. Scand J Gastroenterol 2007; 42: 2–10. 10.1080/0036552060086372017190755
  30. Roman LD, Lukyanchuk R, Sablin OA, Araslanova, EI, Eklund C, Hendolin P, et al. Prevalence of H. pyloriInfection and atrophic gastritis in a population-based screening with serum biomarker panel (GastroPanel®) in St. Petersburg. Anticancer Res 2016; 36: 4129-38.
  31. Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H, Talley NJ, et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol 2008; 43: 1448-55. 10.1080/00365520802273025
  32. Sipponen P, Correa P. Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hypothesis. Gastric Cancer 2002; 5: 213-9. 10.1007/s10120020003712491079
  33. Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2012; 21: 20-38. 10.1158/1055-9965.EPI-11-0834
  34. Sipponen P, Kekki M, Haapakoski J, Ihamäki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1985; 35: 173-7.387173810.1002/ijc.2910350206
  35. Roosendaal R, Kuipers EJ, Buitenwerf J, van Uffelen C, Meuwissen SG, van Kamp GJ, Vandenbroucke-Grauls CM. Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol 1997; 92: 1480-2.9317067
  36. Väänänen H, Vauhkonen M, Helske T, Kääriäinen I, Rasmussen M, Tunturi-Hihnala H, et al. Nonendoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003; 15: 885-91. 10.1097/01.meg.0000059169.46867.01
  37. Gubina M, Tepeš B, Vidmar G, Logar J, Wraber B, Poljanec J, Bricelj I, et al. The prevalence of Helicobacter pylori infection in Slovenia in 2005. ZdravVestn 2006; 75: 169-73.
  38. Benberin V, Bektayeva R, Karabayeva R, Lebedev A, Akemeyeva K, Paloheimo L, et al. Prevalence of H. pylori infection and atrophic gastritis among asymptomatic and dyspeptic adults in Kazakhstan. A Hospital-Based screening with a panel of serum biomarkers. Anticancer Res 2013; 33: 4595-602.24123036
DOI: https://doi.org/10.1515/raon-2017-0054 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 7 - 13
Submitted on: Sep 11, 2017
|
Accepted on: Oct 10, 2017
|
Published on: Dec 7, 2017
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2017 Bojan Tepes, Maja Seruga, Miroslav Vujasinovic, Dejan Urlep, Liljana Ljepovic, Jurecic Nataša Brglez, Alenka Forte, Ljubec Anita Kek, Miha Skvarc, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.